Literature DB >> 9751628

Somatic mutation of TSSC5, a novel imprinted gene from human chromosome 11p15.5.

M P Lee1, C Reeves, A Schmitt, K Su, T D Connors, R J Hu, S Brandenburg, M J Lee, G Miller, A P Feinberg.   

Abstract

We previously reported the isolation of a 2.5 Mb tumor-suppressing subchromosomal transferable fragment (STF) from 11p15.5 and the identification of nine known genes and four novel genes within this STF. We now report the isolation of a fifth novel cDNA, tumor-suppressing STF cDNA 5, designated TSSC5, located within the STF. TSSC5 encodes a predicted protein of 424 amino acids. Sequence analysis suggests that TSSC5 is a membrane protein with 10 transmembrane segments, and it is located between two imprinted genes, p57KIP2 and TSSC3. Northern blot hybridization revealed a 1.6-kb transcript in multiple adult tissues and in fetal liver and kidney, consistent with a potential role in embryonal tumors. We also found that TSSC5 is imprinted with preferential expression from the maternal chromosome. Reverse transcription-PCR analysis of TSSC5 revealed frequent occurrence of aberrant RNA splicing, which deleted exons 4, 5, and 6 in Wilms' tumors. Mutational analysis of TSSC5 by direct DNA sequencing of exons revealed a base substitution of G1120A in a Wilms' tumor, matched normal kidney, and the patient's mother, changed Arg at codon 309 to Gln. The G1120A substitution thus represents either a rare polymorphism or a tumor-predisposing mutation, because the mutant allele was of maternal origin and preferentially expressed in the patient's tissue. A second base substitution, C892T, was found in a lung cancer, changing Ser at codon 233 to Phe. This substitution was absent from the matched normal tissue and thus represented a somatic mutation. We also found loss of heterozygosity in the lung cancer, suggesting that TSSC5 may be a conventional tumor suppressor gene in the adult human lung and an imprinted tumor suppressor gene in the fetal kidney.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9751628

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

Review 1.  Genomic imprinting: implications for human disease.

Authors:  J G Falls; D J Pulford; A A Wylie; R L Jirtle
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

2.  The two-domain hypothesis in Beckwith-Wiedemann syndrome.

Authors:  A P Feinberg
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

3.  Loss of imprinting of a paternally expressed transcript, with antisense orientation to KVLQT1, occurs frequently in Beckwith-Wiedemann syndrome and is independent of insulin-like growth factor II imprinting.

Authors:  M P Lee; M R DeBaun; K Mitsuya; H L Galonek; S Brandenburg; M Oshimura; A P Feinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

4.  In vitro and in vivo radiosensitization of human glioma U251 cells induced by upregulated expression of SLC22A18.

Authors:  S-H Chu; Z-M Zhou; S Karri; Z-Q Li; J-M Zhao
Journal:  Cancer Gene Ther       Date:  2014-01-31       Impact factor: 5.987

5.  Tumor suppressor candidate TSSC5 is regulated by UbcH6 and a novel ubiquitin ligase RING105.

Authors:  H Y Yamada; G J Gorbsky
Journal:  Oncogene       Date:  2006-03-02       Impact factor: 9.867

6.  Targeted disruption of the Kvlqt1 gene causes deafness and gastric hyperplasia in mice.

Authors:  M P Lee; J D Ravenel; R J Hu; L R Lustig; G Tomaselli; R D Berger; S A Brandenburg; T J Litzi; T E Bunton; C Limb; H Francis; M Gorelikow; H Gu; K Washington; P Argani; J R Goldenring; R J Coffey; A P Feinberg
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

7.  Elevated expression of solute carrier family 22 member 18 increases the sensitivity of U251 glioma cells to BCNU.

Authors:  Sheng-Hua Chu; Yan-Bin Ma; Dong-Fu Feng; Hong Zhang; Jian-Hua Qiu; Zhi-An Zhu
Journal:  Oncol Lett       Date:  2011-08-04       Impact factor: 2.967

8.  Impaired expression of an organic cation transporter, IMPT1, in a knockout mouse model for kidney stone disease.

Authors:  Eleni G Tzortzaki; Min Yang; Dayna Glass; Li Deng; Andrew P Evan; Sharon B Bledsoe; Peter J Stambrook; Amrik Sahota; Jay A Tischfield
Journal:  Urol Res       Date:  2003-07-11

9.  Gain of imprinting at chromosome 11p15: A pathogenetic mechanism identified in human hepatocarcinomas.

Authors:  C Schwienbacher; L Gramantieri; R Scelfo; A Veronese; G A Calin; L Bolondi; C M Croce; G Barbanti-Brodano; M Negrini
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

10.  Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy.

Authors:  Sheng-Hua Chu; Yan-Bin Ma; Dong-Fu Feng; Zhi-Qiang Li; Pu-Cha Jiang
Journal:  J Transl Med       Date:  2013-03-20       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.